drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous third-generation anti-CD19 CAR T-cell therapy expressing a CD19-specific scFv with CD28 and CD3ζ activation domains plus a TLR2 co-stimulatory module (1928T2z) to enhance T-cell activation, cytokine production, and persistence; targets CD19+ B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous third‑generation anti‑CD19 CAR T cells engineered with a CD19‑specific scFv and intracellular CD28/CD3ζ activation domains plus a TLR2 co‑stimulatory module (1928T2z). Upon binding CD19 on malignant B cells, the CAR triggers robust T‑cell activation, proliferation, cytokine production, and cytolytic killing, enhancing persistence and leading to depletion of CD19+ B cells (including normal B cells).
drug_name
WZTL-002 CAR T-cells
nct_id_drug_ref
NCT06486051